In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China
- 257 Downloads
Tedizolid is an oxazolidinone with an antimicrobial in vitro potency advantage against Gram-positive bacterial pathogens compared to other currently marketed drugs in this class, including linezolid. Tedizolid was compared to linezolid when tested against Staphylococcus aureus and Streptococcus pneumoniae isolates collected from countries in Latin America and the Asia-Pacific. Isolates were tested by broth microdilution susceptibility methods against tedizolid, linezolid, and non-class comparators in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. The activity of tedizolid against S. aureus was potent and consistent in Latin America (MIC90, 0.5 mg/L), Australia and New Zealand (MIC90, 0.25 mg/L), and China (MIC90, 0.5 mg/L). Based on MIC90 results, tedizolid was four- to eight-fold more active than linezolid against S. aureus, including both methicillin-susceptible and -resistant isolates. Only two tedizolid non-susceptible strains were observed; both had intermediate minimum inhibitory concentration (MIC) values of 1 mg/L, for which the MICs of linezolid was higher (≥2 mg/L). Tedizolid (MIC90, 0.25 mg/L) was four-fold more potent than linezolid (MIC90, 1 mg/L) against S. pneumoniae in all countries that provided isolates. The findings from this study support the global clinical development of tedizolid for Gram-positive infections.
KeywordsMinimum Inhibitory Concentration Linezolid Teicoplanin Daptomycin Oxazolidinones
The authors thank Thomas Lynch and Aubrey Smith for their support in the protocol design, data analysis, and development of this manuscript.
Compliance with ethical standards
This work was supported by Bayer HealthCare Pharmaceuticals.
Conflict of interest
DJB, SKB, BJ, and DFS are employees of International Health Management Associates, Inc. None of the IHMA authors have personal financial interests and have none to declare. JA is an employee of Bayer HealthCare Pharmaceuticals.
These data have not been presented in any other format or other journals and comply with the ethical standards of the journal. This was an in vitro study only and did not include patients or animals; therefore, informed consent was not needed.
- 5.Rybak JM, Roberts K (2015) Tedizolid phosphate: a next-generation Oxazolidinone. Infect Dis Ther [Epub ahead of print]Google Scholar
- 8.Locke JB, Zuill DE, Scharn CR, Deane J, Sahm DF, Goering RV, Jenkins SG, Shaw KJ (2014) Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center. Antimicrob Agents Chemother 58:6949–6952CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA (2015) Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs 75:253–270CrossRefPubMedGoogle Scholar
- 13.Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, Bartizal KF (2015) Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 81:112–118CrossRefPubMedGoogle Scholar
- 16.Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P (2014) Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14:696–705CrossRefPubMedGoogle Scholar
- 18.Clinical and Laboratory Standards Institute (CLSI) (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard—10th edn. CLSI document M07-A10. CLSI, WayneGoogle Scholar
- 19.Clinical and Laboratory Standards Institute (CLSI) (2015) Performance standards for antimicrobial susceptibility testing; Twenty-sixth informational supplement. CLSI document M100-S26. CLSI, Wayne, PAGoogle Scholar